Shares are $2.42 and climbing on more than 2800 trades.
NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study
The editor has bought NRSN on this news and will sell at his discretion
The editor has bought NRSN on this news and will sell at his discretion
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
© 2022-2023 24/7MarketNews – The Experts in Investor and Public Relations